Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Jennifer Yang, Matthew R. Farren, Daniel Ahn, Tanios Bekaii-Saab & Gregory B. Lesinski. (2017) Signaling pathways as therapeutic targets in biliary tract cancer. Expert Opinion on Therapeutic Targets 21:5, pages 485-498.
Read now
Read now
Articles from other publishers (19)
Alba Loras, Marta Gil-Barrachina, María Ángeles Marqués-Torrejón, Gemma Perez-Pastor & Conrado Martinez-Cadenas. (2022) UV-Induced Somatic Mutations Driving Clonal Evolution in Healthy Skin, Nevus, and Cutaneous Melanoma. Life 12:9, pages 1339.
Crossref
Crossref
Stefanie Hoyer, Valentina Eberlein, Gerold Schuler, Carola Berking, Lucie Heinzerling, Niels Schaft & Jan Dörrie. (2021) BRAF and MEK Inhibitors Affect Dendritic-Cell Maturation and T-Cell Stimulation. International Journal of Molecular Sciences 22:21, pages 11951.
Crossref
Crossref
Federico Felizzi, Noman Paracha, Johannes Pöhlmann & Joshua Ray. (2021) Mixture Cure Models in Oncology: A Tutorial and Practical Guidance. PharmacoEconomics - Open 5:2, pages 143-155.
Crossref
Crossref
Meet Patel, Adam Eckburg, Shahina Gantiwala, Zachary Hart, Joshua Dein, Katie Lam & Neelu Puri. (2021) Resistance to Molecularly Targeted Therapies in Melanoma. Cancers 13:5, pages 1115.
Crossref
Crossref
Konstantinos Christofyllakis, Claudia Pföhler, Moritz Bewarder, Cornelia S. L. Müller, Lorenz Thurner, Torben Rixecker, Thomas Vogt, Stephan Stilgenbauer, Krista Yordanova & Dominic Kaddu-Mulindwa. (2021) Adjuvant Therapy of High-Risk (Stages IIC–IV) Malignant Melanoma in the Post Interferon-Alpha Era: A Systematic Review and Meta-Analysis. Frontiers in Oncology 10.
Crossref
Crossref
Debora Basile, Camilla Lisanti, Maria A. Pizzichetta, Paolo Baldo, Giulia Fornasier, Francesco Lo Re, Giuseppe Corona & Fabio Puglisi. (2019) Safety Profiles and Pharmacovigilance Considerations for Recently Patented Anticancer Drugs: Cutaneous Melanoma. Recent Patents on Anti-Cancer Drug Discovery 14:3, pages 203-225.
Crossref
Crossref
Qingliang Yu, Jiayi Xie, Jiangmiao Li, Yunxin Lu & Liang Liao. (2019) Clinical outcomes of BRAF plus MEK inhibition in melanoma: A meta‐analysis and systematic review. Cancer Medicine 8:12, pages 5414-5424.
Crossref
Crossref
Sheng Wang, Dexi Zhou, Zhenyu Xu, Jing Song, Xueyi Qian, Xiongwen Lv & Jiajie Luan. (2019) Anti-tumor Drug Targets Analysis: Current Insight and Future Prospect. Current Drug Targets 20:11, pages 1180-1202.
Crossref
Crossref
K. C. Nicolaou & Stephan Rigol. (2019) The Role of Organic Synthesis in the Emergence and Development of Antibody–Drug Conjugates as Targeted Cancer Therapies. Angewandte Chemie International Edition 58:33, pages 11206-11241.
Crossref
Crossref
Luca Quattrini, Vito Coviello, Stefania Sartini, Teresa Di Desidero, Paola Orlandi, Yi-Yu Ke, Kai-Lun Liu, Hsing-Pang Hsieh, Guido Bocci & Concettina La Motta. (2019) Dual Kit/Aur Inhibitors as Chemosensitizing Agents for the Treatment of Melanoma: Design, Synthesis, Docking Studies and Functional Investigation. Scientific Reports 9:1.
Crossref
Crossref
K. C. Nicolaou & Stephan Rigol. (2019) Die Bedeutung der organischen Synthese bei der Entstehung und Entwicklung von Antikörper‐Wirkstoff‐Konjugaten als gezielte Krebstherapien. Angewandte Chemie.
Crossref
Crossref
Maya Habre, Antoine Salloum, Samer Bassilios Habre, Joanna Abi Chebl, Racha Dib & Hampig Raphael Kourie. (2019) Skin adverse events in recently approved targeted therapies in solid malignancies. Future Oncology 15:3, pages 331-343.
Crossref
Crossref
B.M.E. Tullemans, J.W.M. Heemskerk & M.J.E. Kuijpers. (2018) Acquired platelet antagonism: off‐target antiplatelet effects of malignancy treatment with tyrosine kinase inhibitors. Journal of Thrombosis and Haemostasis 16:9, pages 1686-1699.
Crossref
Crossref
Jan Dörrie, Lek Babalija, Stefanie Hoyer, Kerstin Gerer, Gerold Schuler, Lucie Heinzerling & Niels Schaft. (2018) BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy. International Journal of Molecular Sciences 19:1, pages 289.
Crossref
Crossref
Amber JohnsonYekaterina B. KhotskayaLauren BruscoJia ZengVijaykumar HollaAnn M. BaileyBeate C. LitzenburgerNora S. SánchezMd Abu ShufeanSarina Piha-PaulVivek SubbiahDavid HongMark RoutbortRussell BroaddusKenna R. Mills ShawGordon B. MillsJohn MendelsohnFunda Meric-Bernstam. (2017) Clinical Use of Precision Oncology Decision Support. JCO Precision Oncology:1, pages 1-12.
Crossref
Crossref
Amélie Boespflug, Elisa Funck‐Brentano, Zofia Hélias‐Rodzewicz, Delphine Maucort‐Boulch, Alain Beauchet, Pierre‐Paul Bringuier, Charles Dumontet, Jean‐François Emile, Philippe Saiag & Stéphane Dalle. (2017)
Reply to “Clinical and therapeutic implications of
BRAF
mutation heterogeneity in metastatic melanoma” by Mesbah Ardakani et al.
. Pigment Cell & Melanoma Research 30:5, pages 498-500.
Crossref
Crossref
Min You, Dao Nguyen, Lynn G. Feun, M.T. Kuo, Medhi Wangpaichitr, Chunjing Wu & Niramol Savaraj. 2017. Autophagy: Cancer, Other Pathologies, Inflammation, Immunity, Infection, and Aging. Autophagy: Cancer, Other Pathologies, Inflammation, Immunity, Infection, and Aging
473
487
.
Dean T. Williams & Christopher J. Staples. 2017. Personalised Medicine. Personalised Medicine
1
16
.
Michael P. Smith & Claudia Wellbrock. (2016) Molecular Pathways: Maintaining MAPK Inhibitor Sensitivity by Targeting Nonmutational Tolerance. Clinical Cancer Research 22:24, pages 5966-5970.
Crossref
Crossref